Analyzing the Price-to-Earnings Ratio of GRI Bio Inc (GRI)

The 36-month beta value for GRI is also noteworthy at -1.78. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

The public float for GRI is 0.92M, and at present, short sellers hold a 12.58% of that float. The average trading volume of GRI on April 03, 2024 was 733.45K shares.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

GRI) stock’s latest price update

The stock price of GRI Bio Inc (NASDAQ: GRI) has dropped by -26.26 compared to previous close of 0.75. Despite this, the company has seen a fall of -28.68% in its stock price over the last five trading days. GlobeNewsWire reported 2024-03-28 that Live webcast on Wednesday, April 3 rd at 10:10 AM ET LA JOLLA, CA, March 28, 2024 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will present at the MedInvest Biotech & Pharma Investor Conference being held in New York City, NY on Wednesday, April 3, 2024 at 10:10 AM ET. In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

GRI’s Market Performance

GRI Bio Inc (GRI) has seen a -28.68% fall in stock performance for the week, with a -32.56% decline in the past month and a -79.48% plunge in the past quarter. The volatility ratio for the week is 12.65%, and the volatility levels for the past 30 days are at 8.44% for GRI. The simple moving average for the past 20 days is -30.37% for GRI’s stock, with a -94.78% simple moving average for the past 200 days.

GRI Trading at -52.27% from the 50-Day Moving Average

After a stumble in the market that brought GRI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.52% of loss for the given period.

Volatility was left at 8.44%, however, over the last 30 days, the volatility rate increased by 12.65%, as shares sank -33.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -70.96% lower at present.

During the last 5 trading sessions, GRI fell by -28.68%, which changed the moving average for the period of 200-days by -98.80% in comparison to the 20-day moving average, which settled at $0.7800. In addition, GRI Bio Inc saw -79.48% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for GRI

Current profitability levels for the company are sitting at:

  • -2.36 for the present operating margin
  • 1.0 for the gross margin

The net margin for GRI Bio Inc stands at -2.47. The total capital return value is set at -49.22. Equity return is now at value -1021.38, with -373.75 for asset returns.

Based on GRI Bio Inc (GRI), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -642.14. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -12.99.

Currently, EBITDA for the company is -11.33 million with net debt to EBITDA at 0.14. When we switch over and look at the enterprise to sales, we see a ratio of -0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.09.

Conclusion

In summary, GRI Bio Inc (GRI) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts